Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes.
Disordered eating
Gut microbiota
Insulin restriction
Obesity
Short-chain fatty acids
Type 1 diabetes
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
11
04
2022
revised:
05
11
2022
accepted:
10
11
2022
pmc-release:
01
02
2024
pubmed:
1
1
2023
medline:
15
2
2023
entrez:
31
12
2022
Statut:
ppublish
Résumé
Disordered eating (DE) in type 1 diabetes (T1D) includes insulin restriction for weight loss with serious complications. Gut microbiota-derived short chain fatty acids (SCFA) may benefit host metabolism but are reduced in T1D. We evaluated the hypothesis that DE and insulin restriction were associated with reduced SCFA-producing gut microbes, SCFA, and intestinal microbial diversity in adults with T1D. We collected stool samples at four timepoints in a hypothesis-generating gut microbiome pilot study ancillary to a weight management pilot in young adults with T1D. 16S ribosomal RNA gene sequencing measured the normalized abundance of SCFA-producing intestinal microbes. Gas-chromatography mass-spectrometry measured SCFA (total, acetate, butyrate, and propionate). The Diabetes Eating Problem Survey-Revised (DEPS-R) assessed DE and insulin restriction. Covariate-adjusted and Bonferroni-corrected generalized estimating equations modeled the associations. COVID-19 interrupted data collection, so models were repeated restricted to pre-COVID-19 data. Data were available for 45 participants at 109 visits, which included 42 participants at 65 visits pre-COVID-19. Participants reported restricting insulin "At least sometimes" at 53.3% of visits. Pre-COVID-19, each 5-point DEPS-R increase was associated with a -0.34 (95% CI -0.56, -0.13, p = 0.07) lower normalized abundance of genus Anaerostipes; and the normalized abundance of Lachnospira genus was -0.94 (95% CI -1.5, -0.42), p = 0.02 lower when insulin restriction was reported "At least sometimes" compared to "Rarely or Never". DE and insulin restriction were associated with a reduced abundance of SCFA-producing gut microbes pre-COVID-19. Additional studies are needed to confirm these associations to inform microbiota-based therapies in T1D.
Sections du résumé
BACKGROUND AND AIMS
Disordered eating (DE) in type 1 diabetes (T1D) includes insulin restriction for weight loss with serious complications. Gut microbiota-derived short chain fatty acids (SCFA) may benefit host metabolism but are reduced in T1D. We evaluated the hypothesis that DE and insulin restriction were associated with reduced SCFA-producing gut microbes, SCFA, and intestinal microbial diversity in adults with T1D.
METHODS AND RESULTS
We collected stool samples at four timepoints in a hypothesis-generating gut microbiome pilot study ancillary to a weight management pilot in young adults with T1D. 16S ribosomal RNA gene sequencing measured the normalized abundance of SCFA-producing intestinal microbes. Gas-chromatography mass-spectrometry measured SCFA (total, acetate, butyrate, and propionate). The Diabetes Eating Problem Survey-Revised (DEPS-R) assessed DE and insulin restriction. Covariate-adjusted and Bonferroni-corrected generalized estimating equations modeled the associations. COVID-19 interrupted data collection, so models were repeated restricted to pre-COVID-19 data. Data were available for 45 participants at 109 visits, which included 42 participants at 65 visits pre-COVID-19. Participants reported restricting insulin "At least sometimes" at 53.3% of visits. Pre-COVID-19, each 5-point DEPS-R increase was associated with a -0.34 (95% CI -0.56, -0.13, p = 0.07) lower normalized abundance of genus Anaerostipes; and the normalized abundance of Lachnospira genus was -0.94 (95% CI -1.5, -0.42), p = 0.02 lower when insulin restriction was reported "At least sometimes" compared to "Rarely or Never".
CONCLUSION
DE and insulin restriction were associated with a reduced abundance of SCFA-producing gut microbes pre-COVID-19. Additional studies are needed to confirm these associations to inform microbiota-based therapies in T1D.
Identifiants
pubmed: 36586772
pii: S0939-4753(22)00460-4
doi: 10.1016/j.numecd.2022.11.017
pmc: PMC9925402
mid: NIHMS1850812
pii:
doi:
Substances chimiques
Fatty Acids, Volatile
0
Insulin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
388-398Subventions
Organisme : NIDDK NIH HHS
ID : DP3 DK113358
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056350
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL129969
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI125800
Pays : United States
Informations de copyright
Copyright © 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare no competing interests.
Références
PLoS One. 2015 May 29;10(5):e0126685
pubmed: 26024217
Diabetes Obes Metab. 2023 Mar;25(3):688-699
pubmed: 36314293
Sci Rep. 2021 Jul 26;11(1):15208
pubmed: 34312454
Diabetes Care. 2017 Dec;40(12):1756-1762
pubmed: 29138273
Diabetes. 2008 Oct;57(10):2555-62
pubmed: 18820210
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
ISME J. 2020 Jul;14(7):1809-1820
pubmed: 32313261
Diabetes Care. 2018 Nov;41(11):2385-2395
pubmed: 30224347
Chin Med J (Engl). 2016 Jun 5;129(11):1298-304
pubmed: 27231166
Sci Rep. 2014 Jan 22;4:3814
pubmed: 24448554
Nat Commun. 2021 Aug 10;12(1):4798
pubmed: 34376656
Clin Nutr. 2021 Jun;40(6):3859-3867
pubmed: 34130033
Science. 2013 Jul 5;341(6141):1237439
pubmed: 23828941
Diabetes Care. 2005 Jan;28(1):84-8
pubmed: 15616238
Br J Nutr. 2016 Jul;116(1):80-93
pubmed: 27151248
Nat Commun. 2013;4:1829
pubmed: 23652017
Diabetes. 2013 Apr;62(4):1238-44
pubmed: 23274889
Pediatr Diabetes. 2010 Feb;11(1):4-11
pubmed: 19473302
BMJ. 1995 Jan 21;310(6973):170
pubmed: 7833759
Pediatr Diabetes. 2015 Nov;16(7):485-92
pubmed: 26269193
J Eat Disord. 2021 Jan 6;9(1):6
pubmed: 33407910
Diabetes Care. 2008 Mar;31(3):415-9
pubmed: 18070998
Gene. 2014 Mar 1;537(1):85-92
pubmed: 24325907
Diabetes Care. 2010 Mar;33(3):495-500
pubmed: 20032278
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 May;1866(5):158900
pubmed: 33571672
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Nutrients. 2020 Jul 17;12(7):
pubmed: 32708978
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
Eur Eat Disord Rev. 2017 Sep;25(5):423-427
pubmed: 28586130
J Endocrinol Invest. 2005 May;28(5):417-9
pubmed: 16075924
J Nutr. 2017 Jan;147(1):20-28
pubmed: 27903830
Scand J Gastroenterol. 1984 May;19(3):375-81
pubmed: 6740214
Diabetes Care. 2001 Oct;24(10):1711-21
pubmed: 11574431
J Med Food. 2005 Spring;8(1):113-6
pubmed: 15857221
Int J Eat Disord. 2008 Apr;41(3):259-64
pubmed: 18095311
Nature. 2012 May 09;486(7402):222-7
pubmed: 22699611
Biopsychosoc Med. 2021 Nov 29;15(1):25
pubmed: 34844634
J Acad Nutr Diet. 2022 Jun;122(6):1089-1098
pubmed: 35033698
Int J Eat Disord. 2021 Jul;54(7):1189-1201
pubmed: 33720460
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33472859
Brain Behav Immun. 2017 Nov;66:9-17
pubmed: 28131791
Lancet Diabetes Endocrinol. 2015 Mar;3(3):207-15
pubmed: 25066177
Obesity (Silver Spring). 2010 Jan;18(1):190-5
pubmed: 19498350
Mol Aspects Med. 2013 Feb;34(1):39-58
pubmed: 23159341
PLoS One. 2011;6(10):e25792
pubmed: 22043294
Curr Diab Rep. 2017 Aug;17(8):58
pubmed: 28660565
Metabolism. 2004 May;53(5):655-9
pubmed: 15131773
J Physiol. 2017 Jan 15;595(2):541-555
pubmed: 27510655
Nutrients. 2013 Mar 12;5(3):829-51
pubmed: 23482058
Clin Trials. 2014 Apr 14;11(4):445-456
pubmed: 24733671
Diabetes Care. 2004 Jul;27(7):1654-9
pubmed: 15220242
PLoS One. 2017 Dec 6;12(12):e0188475
pubmed: 29211757
J Proteome Res. 2021 Jul 2;20(7):3642-3653
pubmed: 34048241
mSystems. 2016 May 3;1(3):
pubmed: 27822526
ISME J. 2019 Aug;13(8):1911-1919
pubmed: 30894688
Nat Commun. 2021 May 28;12(1):3105
pubmed: 34050144
J Eat Disord. 2019 Jan 17;7:2
pubmed: 30675355
Psychosom Med. 2015 Nov-Dec;77(9):969-81
pubmed: 26428446
Front Nutr. 2018 Nov 29;5:119
pubmed: 30555830
J Clin Med. 2022 Jun 21;11(13):
pubmed: 35806857
Diabet Med. 2017 Jan;34(1):127-134
pubmed: 27100052
Microbiome. 2017 May 5;5(1):52
pubmed: 28476139
PLoS One. 2009 Sep 23;4(9):e7125
pubmed: 19774074
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
BMC Med. 2013 Feb 21;11:46
pubmed: 23433344
Sci Rep. 2015 Nov 17;5:16350
pubmed: 26572876
Front Cell Infect Microbiol. 2020 Feb 25;10:63
pubmed: 32158702
Talanta. 2019 May 1;196:249-254
pubmed: 30683360
Sci Rep. 2016 May 27;6:26752
pubmed: 27229737
PLoS One. 2021 Nov 15;16(11):e0257154
pubmed: 34780485
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Contemp Clin Trials. 2022 Jun;117:106765
pubmed: 35460915
Diabetes Care. 2013 Aug;36(8):2346-50
pubmed: 23564922
Cell Host Microbe. 2015 Feb 11;17(2):260-73
pubmed: 25662751
ISME J. 2011 Jan;5(1):82-91
pubmed: 20613793
Gut Microbes. 2021 Jan-Dec;13(1):1-18
pubmed: 33615984
Front Microbiol. 2019 Oct 23;10:2407
pubmed: 31708888
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1247-1256
pubmed: 35080610
Environ Microbiol. 2010 Feb;12(2):304-14
pubmed: 19807780
Nat Rev Endocrinol. 2015 Oct;11(10):577-91
pubmed: 26260141
Clin Nutr. 2021 Apr;40(4):2035-2044
pubmed: 33023763